QIAGEN N.V. logo

QIAGEN N.V. (QGE4)

Market Closed
17 Jul, 15:30
36. 00
-0.2
-0.5525%
- Market Cap
26.32 P/E Ratio
1.28% Div Yield
11,440 Volume
2.11 Eps
36.2
Previous Close
Add Transaction
Day Range
36 36.6
Year Range
28.4 47.5
Want to track QGE4 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

QGE4 closed yesterday lower at €36, a decrease of -0.5525% from Thursday's close, completing a monthly increase of 4.0462% or €1.4. Over the past 12 months, QGE4 stock lost -11.6507%.
QGE4 pays dividends to its shareholders, with the most recent payment made on Jul 14, 2026. The next estimated payment will be in In 5 months on Jan 14, 2027 for a total of €0.35.
The last earnings report, released on May 05, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0067%, based on the last three reports.
QIAGEN N.V. has completed 2 stock splits, with the recent split occurring on Jan 08, 2026.
The company's stock is traded on 11 different exchanges and in various currencies, with the primary listing on NYSE (USD).

QGE4 Chart

Qiagen: New Launches Signal A Turnaround

Qiagen: New Launches Signal A Turnaround

Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation.

Seekingalpha | 6 days ago
Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript

Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript

Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript

Seekingalpha | 1 month ago
QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use

QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use

QGEN's QIAcuity expansion adds gene expression assays, multiplexing, automation and analysis tools to drive dPCR adoption.

Zacks | 1 month ago

QIAGEN N.V. (QGE4) FAQ

What is the stock price today?

The current price is €36.00.

On which exchange is it traded?

QIAGEN N.V. is listed on XWBO.

What is its stock symbol?

The ticker symbol is QGE4.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.28%.

What is its market cap?

As of today, no market cap data is available.

Has QIAGEN N.V. ever had a stock split?

QIAGEN N.V. had 2 splits and the recent split was on Jan 08, 2026.

QIAGEN N.V. Profile

Professional Services Industry
Industrials Sector
Thierry Bernard CEO
XWBO Exchange
NL0015002SN0 ISIN
NL Country
5,736 Employees
7 Jul 2026 Last Dividend
8 Jan 2026 Last Split
28 Jun 1996 IPO Date

Overview

Founded in 1984 and headquartered in Venlo, the Netherlands, QIAGEN N.V. is a global leader in providing comprehensive solutions that convert biological materials into valuable molecular insights. The company’s innovative portfolio spans a wide range of sectors including molecular diagnostics, academia, pharmaceutical, and applied testing. QIAGEN is dedicated to facilitating the process of acquiring insights from biological samples through its extensive array of technologies and products, designed to support various stages of molecular analysis.

Products and Services

  • Sample Technology Consumables: QIAGEN offers an array of consumables for sample preparation, including nucleic acid stabilization and purification kits tailored for an array of primary sample materials. They provide solutions for manual and automated processing that support genotyping, gene expression analysis, and the assessment of viral and bacterial loads. Technologies include silica membranes and magnetic bead-based approaches.
  • Nucleic Acid Purification Instruments: The company manufactures instruments that enable the purification of nucleic acids along with necessary accessories, helping streamline the preparation process in laboratories.
  • PCR Consumables and Instruments: QIAGEN offers a comprehensive portfolio of PCR consumables, including quantitative PCR (qPCR) and reverse transcription kits designed for various analyses such as gene expression, genotyping, and gene regulation. This category also encompasses a range of PCR instruments, including innovative solutions for digital PCR and qPCR, designed for precision and efficiency.
  • Human ID and Forensics: The company provides assay consumables for human identification (ID) and forensic purposes, including Short Tandem Repeat (STR) assays and tests for detecting food contamination.
  • Assays for Various Diseases and Conditions: QIAGEN develops interferon-gamma release assays for Tuberculosis (TB) testing, along with assays for post-transplant monitoring, viral load determination, prenatal testing, detection of sexually transmitted diseases (STDs), and the Human Papillomavirus (HPV). These offerings are crucial for early detection and monitoring of various conditions and diseases.
  • Genomic Variant Analysis: The company provides assays designed for the detailed analysis of genomic variants, such as mutations, insertions, deletions, and fusions. This is crucial for understanding genetic diseases and tailoring personalized medicine approaches.
  • Next-Generation Sequencing (NGS): QIAGEN’s NGS solutions include predefined and custom gene panels, library preparation kits, and whole genome amplification products. These enable researchers and clinicians to conduct comprehensive genomic studies and leverage sequencing for diagnostics and research purposes.
  • Bioinformatics and Custom Services: In addition to physical products, QIAGEN provides bioinformatics solutions for data analysis and interpretation, as well as custom laboratory and genomic services tailored to meet specific research needs, enabling customers to achieve their unique objectives in molecular analysis.

Contact Information

Address: Hulsterweg 82
Phone: 31 77 355 6600